Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study

R H Jensen, H K Johansen, L M Søes, Lars Erik Lemming, F. S. Rosenvinge, L. Nielsen, B Olesen, L Kristensen, Esad Dzajic, K. M. T. Astvad, M C Arendrup

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

175 Downloads (Pure)

Abstract

The prevalence of intrinsic and acquired resistance among colonizing Candida isolates from patients after candidemia was investigated systematically in a 1-year nationwide study. Patients were treated at the discretion of the treating physician. Oral swabs were obtained after treatment. Species distributions and MIC data were investigated for blood and posttreatment oral isolates from patients exposed to either azoles or echinocandins for <7 or >= 7 days. Species identification was confirmed using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) and internal transcribed spacer (ITS) sequencing, susceptibility was examined by EUCAST EDef 7.2 methodology, echinocandin resistance was examined by FKS sequencing, and genetic relatedness was examined by multilocus sequence typing (MLST). One hundred ninety-three episodes provided 205 blood and 220 oral isolates. MLST analysis demonstrated a genetic relationship for 90% of all paired blood and oral isolates. Patients exposed to azoles for >= 7 days (n = 93) had a significantly larger proportion of species intrinsically less susceptible to azoles (particularly Candida glabrata) among oral isolates than among initial blood isolates (36.6% versus 12.9%; P < 0.001). A similar shift toward species less susceptible to echinocandins among 85 patients exposed to echinocandins for >= 7 days was not observed (4.8% of oral isolates versus 3.2% of blood isolates; P > 0.5). Acquired resistance in Candida albicans was rare (<5%). However, acquired resistance to fluconazole (29.4%; P < 0.05) and anidulafungin (21.6%; P < 0.05) was common in C. glabrata isolates from patients exposed to either azoles or echinocandins. Our findings suggest that the colonizing mucosal microbiota may be an unrecognized reservoir of resistant Candida species, especially C. glabrata, following treatment for candidemia. The resistance rates were high, raising concern in general for patients exposed to antifungal drugs.
OriginalsprogEngelsk
TidsskriftAntimicrobial Agents and Chemotherapy
Vol/bind60
Udgave nummer3
Sider (fra-til)1500-1508
ISSN0066-4804
DOI
StatusUdgivet - mar. 2016

Bibliografisk note

ISI Document Delivery No.: DM6VM Times Cited: 4 Cited Reference Count: 54 Jensen, R. H. Johansen, H. K. Soes, L. M. Lemming, L. E. Rosenvinge, F. S. Nielsen, L. Olesen, B. Kristensen, L. Dzajic, E. Astvad, K. M. T. Arendrup, M. C. Hare, Rasmus Kroger/0000-0002-9796-023X Gilead Sciences (Gilead) [IXDK 131 0286]; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Gilead Sciences (Gilead) provided funding to Rasmus Hare Jensen under grant number IX DK 131 0286. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) provided funding to Rasmus Hare Jensen under grant number Research Grant 2013. 4 3 Amer soc microbiology Washington 1098-6596

Fingeraftryk

Dyk ned i forskningsemnerne om 'Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study'. Sammen danner de et unikt fingeraftryk.

Citationsformater